Delving into the Latest Updates on Dasatinib with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

anh. dasatinib, Anhydrous dasatinib, BMS dasatinib

+ [23]

Target

EphA2 x FYN x LCK x PDGFRβ x SRC x YES1 x c-Kit

Action

antagonists, inhibitors

Mechanism

EphA2 antagonists(Ephrin type-A receptor 2 antagonists), FYN inhibitors(Tyrosine-protein kinase FYN inhibitors), LCK inhibitors(Tyrosine-protein kinase LCK inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [6]

Active Indication

Aggressive-Phase Chronic Myelocytic LeukemiaPhiladelphia chromosome-positive chronic myeloid leukemia in chronic phasePhiladelphia chromosome positive chronic myelogenous leukemia+ [13]

Inactive Indication

Acral Lentiginous Malignant MelanomaAcute Myeloid LeukemiaAcute Promyelocytic Leukemia+ [78]

Originator Organization

Bristol Myers Squibb Co.

Active Organization

Accord Healthcare SL

Wayne State University Foundation

GSK Plc

+ [11]

Inactive Organization

Otsuka Pharmaceutical Development & Commercialization, Inc.

Celgene Corp.

OSI Pharmaceuticals, Inc.

+ [2]

License Organization

Eversana Life Science Services LLC

Handa Pharmaceuticals, Inc.

Cycle Pharmaceuticals Ltd.

+ [5]

Drug Highest PhaseApproved

First Approval Date

United States (28 Jun 2006),

Acute Lymphoblastic LeukemiaBlast Phase Chronic Granulocytic LeukemiaChronic phase chronic myeloid leukemia

RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (Japan), Orphan Drug (Australia)

Login to view timeline

Structure/Sequence

Molecular FormulaC22H28ClN7O3S

InChIKeyXHXFZZNHDVTMLI-UHFFFAOYSA-N

CAS Registry863127-77-9

This study will test if the medicine dasatinib can lower the hidden amount of HIV in the body, called the HIV "reservoir." It will also check if dasatinib is safe and easy to take for people living with HIV who have a suppressed viral load while on antiretroviral therapy (ART). Adults 18 years or older who have been on ART for at least 48 months and have had a suppressed HIV-1 viral load for at least 36 months may be able to join.
People will be randomly assigned to take dasatinib 100 mg by mouth once a day or a look-alike substance with no drug, called a placebo, for 12 weeks. Neither participants nor researchers will know who gets which (double-blind). The study team will do regular health checks and blood tests to track safety, tolerability, the HIV reservoir, and changes in immune cells.
The study lasts 36 weeks total: 12 weeks of treatment and 24 weeks of follow-up, with clinic visits and possible phone calls. Fourteen people will take part; eight will get dasatinib and six will get placebo. Dasatinib may lower the HIV reservoir, but this is not guaranteed. All medicines can cause side effects, called adverse events (AE). The study team will watch closely and provide medical support. Joining is your choice, and you can leave at any time. If you leave, the team will talk with you about next steps for your care.

Start Date30 Apr 2026

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

NCT07493408

/ Not yet recruitingPhase 2IIT

Efficacy and Safety of Adding Asciminib to the Standard-of-care for Post Allogenic Hematopoietic Stem-cell Transplant (HSCT) Maintenance in Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (Ph+ B-ALL) or Blastic Transformed CML (Myeloid or Lymphoid) (CML-BP)

The goal of this clinical trial is to learn if Asciminib, a first in class allosteric inhibitor, as a add-on maintenance therapy can provides benefits and further prevents relapse in post allogenic hematopoietic stem-cell transplant (HSCT) of patients with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL) or blastic transformed Chronic Myeloid Leukemia (CML-BP).
The main questions it aims to answer are:
Would Ascminib add-on maintenance therapyimprove Morphological relapse-free survival rate? Would Ascminib add-on maintenance therapy improve Molecular relapse-free survival and Overall survival ? Any toxicity or intolerable events during Ascminib add-on maintenance therapy?
Researchers will compare Study arm (Ascminib plus tyrosine-kinase inhibitors [TKIs]) and Control arm (TKIs only) to see if Ascminib add-on maintenance therapy would provide better relapse-free survival (RFS) with optimal tolerability.
Participants will
* Enrolled and Randomized into either Study arm or Control arm
* Take Ascminib plus selected TKI or selected TKI only according to schedule
* Visit the clinic once every 2-4 weeks for checkups and tests
* Record and Report any adverse event and graft-versus-host-disease (GvHD) development

Start Date30 Mar 2026

Sponsor / Collaborator

The University of Hong Kong

[+2]

100 Clinical Results associated with Dasatinib

Login to view more data

100 Translational Medicine associated with Dasatinib

Login to view more data

100 Patents (Medical) associated with Dasatinib

Login to view more data

6,734

Literatures (Medical) associated with Dasatinib

01 Apr 2026·AMERICAN JOURNAL OF HEMATOLOGY

The Care and Cure of the Leukemias in 2026

Review

Author: Wierda, William ; Kantarjian, Hagop ; Kadia, Tapan ; Haddad, Fadi G. ; Freireich, Emil J. ; Ravandi, Farhad ; Chifotides, Helen T. ; Jabbour, Elias ; Jain, Nitin ; Welch, Mary Alma

ABSTRACT:

It is an exciting era in leukemia owing to the development of novel targeted therapies and advances in genomics, pathophysiology, prognostication, and monitoring (e.g., highly sensitive measurable residual disease assays). Currently, most leukemias are effectively treated with immunotherapies (highly effective monoclonal antibodies targeting CD19 [blinatumomab], or CD22 [inotuzumab ozogamicin]), BCR::ABL1 tyrosine kinase inhibitors (TKIs; e.g., dasatinib, ponatinib), Bruton TKIs (e.g., ibrutinib, acalabrutinib), BCL‐2 inhibitors (venetoclax), IDH1/2 inhibitors (ivosidenib, olutasidenib, and enasidenib), FLT3 inhibitors (e.g., midostaurin, quizartinib, and gilteritinib), menin inhibitors (revumenib, ziftomenib), and chimeric antigen receptor T‐cell therapies. These novel agents and their judicious use in combination strategies have transformed the treatment landscape across all leukemias, significantly increased survival and quality of life for patients, and attenuated the need for intensive chemotherapy and hematopoietic stem cell transplantation. Leukemia subtypes, such as Philadelphia‐positive acute lymphoblastic leukemia (incurable before 2000) and chronic lymphocytic leukemia (previously considered incurable) with historically dire prognoses were recently transformed to favorable leukemias with 5‐ and 10‐year survival rates of 80+% and 90+%, respectively. The BCR::ABL1 TKIs resulted in normal life expectancy in chronic myeloid leukemia. Notable advances have also been made in AML with targeted therapies, although some subsets (older/unfit patients for intensive chemotherapy, complex karyotype, TP53 ‐mutated, KMT2A ‐rearranged, and treated secondary AML) still have unfavorable outcomes. Herein, we provide a high‐level overview of prominent clinical developments across all leukemias. In contemporary times, harnessing the benefits of novel targeted therapies and the evolving treatment landscape bolster the optimistic view that most, if not all, leukemias are curable.

01 Apr 2026·PEDIATRIC BLOOD & CANCER

Combined Tyrosine Kinase Inhibitors and Chemotherapy Based on Minimal Residual Disease in Children With Ph ⁺ Acute Lymphoblastic Leukemia: A Phase 2 Single‐Arm Trial, JCCG ALL‐Ph13

Article

Author: Yonezawa, Sachiko ; Sato, Atsushi ; Iijima‐Yamashita, Yuka ; Shima, Haruko ; Kiyokawa, Nobutaka ; Kosaka, Yoshiyuki ; Ito, Etsuro ; Sakaguchi, Hirotoshi ; Deguchi, Takao ; Oshima, Koichi ; Ohki, Kentaro ; Horibe, Keizo ; Kato, Motohiro ; Inoue, Akiko ; Hasegawa, Daisuke ; Kodama, Yuichi ; Kawasaki, Hirohide ; Kato, Keisuke ; Imamura, Chiyo K. ; Manabe, Atsushi ; Sakaguchi, Kimiyoshi ; Shimada, Hiroyuki ; Hashii, Yoshiko ; Yamamoto, Masaki ; Kada, Akiko ; Saito, Akiko Moriya ; Hiramatsu, Hidefumi

ABSTRACT:

Background:

Patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph + ALL) have a poor prognosis. In Ph+ALL04, allogeneic hematopoietic stem cell transplantation (HSCT) in first complete remission (CR) was indicated for all patients, and was performed in those who remained in CR at the scheduled time of transplantation, with 4‐year event‐free survival (EFS) and overall survival (OS) rates of 54% (95% confidence interval [CI]: 38%–68%) and 78% (95% CI: 62%–88%), respectively.

Procedure:

The Japan Children's Cancer Group conducted ALL‐Ph13, a multicenter single‐arm Phase 2 clinical trial, to improve outcomes and reduce HSCTs by using chemotherapy with tyrosine kinase inhibitors (TKIs) guided by minimal residual disease (MRD). The primary endpoint was the 3‐year EFS rate.

Results:

Between 2013 and 2017, 41 of 43 enrolled patients with Ph + ALL aged 1–19 years were eligible. Imatinib was started on Day 15 of induction and switched to dasatinib if MRD‐positive after consolidation IB. TKIs were administered until the end of maintenance treatment (Week 104), with temporary discontinuation due to the severity of nonhematological adverse events and resumption at 80% of the original dose. When MRD was positive after the three HR blocks, HSCT was performed. Following four sepsis‐related deaths, the protocol was amended in 2016, after which no such deaths occurred. Six patients (15%) underwent HSCT in the first CR, one per protocol indication and five without. The 3‐year EFS and OS rates were 65% (95% CI: 48%–78%) and 85% (95% CI: 70%–93%), respectively. As several relapses occurred beyond 3 years, the 5‐year EFS and OS rates were also calculated: 48% (95% CI: 30%–64%) and 85% (95% CI: 70%–93%), respectively.

Conclusions:

Compared with Ph+ALL04, HSCT was substantially reduced in ALL‐Ph13 while maintaining comparable outcomes. Further optimization of treatment, particularly the duration of TKI administration, is needed to maintain long‐term EFS.

01 Apr 2026·Translational Oncology

Construction and validation of golgi apparatus-related genes as predictors of the immune microenvironment and prognosis in colorectal cancer

Article

Author: Wang, Feng ; Chen, Jie

BACKGROUND:

Colorectal cancer (CRC) is the third most common cancer globally, and the identification of novel biomarkers remains an urgent priority in clinical practice and research. Although the Golgi apparatus plays a crucial role in tumorigenesis and cancer progression, its role in CRC remains unclear.

METHODS:

A comprehensive bioinformatics analysis of the transcriptome was conducted using the TCGA and GSE87211 datasets. A reliable risk signature model based on Golgi apparatus - related genes (GARGs) was constructed. Subsequently, we performed an in - depth single - cell RNA sequencing analysis. Finally, based on the consistent evidence across all analytical layers, GDI1 was selected for subsequent functional validation in cellular assays.

RESULTS:

By integrating univariate Cox regression and LASSO analysis, we identified a five-GARG signature to construct a prognostic model. This model stratified patients into high- and low-risk groups with significantly different overall survival. The high-risk group was associated with elevated stromal and ESTIMATE scores, along with increased infiltration of monocytes and M0 macrophages, suggesting a potentially more immunosuppressive and tumor-promoting microenvironment. Bioinformatic predictions indicated that the high-risk group might show enhanced sensitivity to Dasatinib, Sapitinib, and SB216763; this was preliminarily supported by our subsequent in vitro drug sensitivity assays. Cell-cell communication analysis suggested that macrophages might primarily influence the microenvironment through the tumor necrosis factor (TNF) signaling pathway. Critically, functional experiments demonstrated that silencing GDI1 significantly inhibited cell proliferation and migration and induced apoptosis, supporting its potential oncogenic role in COAD.

CONCLUSION:

Collectively, our work links GARG expression to CRC prognosis and immune features, and functionally implicates GDI1 in tumor cell aggressiveness, supporting its further study as a potential therapeutic target.

128

News (Medical) associated with Dasatinib

25 Mar 2026

·allsci.com

Merck acquires Terns for USD 6.7b to boost hematology pipeline with CML drug

Merck (NYSE: MRK) has entered into a definitive agreement to acquire Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage oncology company, for USD 53.00 per share in an all-cash transaction valued at approximately USD 6.7 billion. The Merck Terns Pharmaceuticals acquisition positions the pharma company to consolidate its presence in hematology through TERN-701, an oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase I/II development for chronic myeloid leukemia. The transaction represents approximately USD 5.7 billion net of acquired cash and carries a premium of 31% to the 60-day and 42% to the 90-day volume-weighted average stock price as of March 24, 2026. The deal contains no disclosed milestone payments, contingent value rights, or earn-out provisions. Merck will execute the acquisition through a tender offer requiring a majority of Terns stockholders to tender their shares, with closing expected in Q2 2026 following expiration of the Hart-Scott-Rodino waiting period. The transaction will be accounted for as an asset acquisition, resulting in an approximately USD 5.8 billion charge (approximately USD 2.35 per share) recognized in both Q2 and full-year 2026 GAAP and non-GAAP results. The asset acquisition classification means the acquired in-process R&D will be expensed immediately rather than capitalized. TERN-701: Mechanism and clinical status TERN-701 is a BCR-ABL1 tyrosine kinase inhibitor designed to bind to the ABL myristoyl pocket, an allosteric site distinct from the ATP-binding domain targeted by earlier-generation TKIs. CML is driven by the Philadelphia chromosome, a translocation between chromosomes 9 and 22 that produces constitutive activation of the BCR::ABL1 fusion protein, which fuels malignant white blood cell proliferation. The compound is being evaluated in the CARDINAL trial (NCT06163430), a global multi-center dose escalation and expansion study enrolling patients with Ph+ chronic phase CML who experienced treatment failure, suboptimal response, or intolerance to at least one prior TKI. The dose escalation portion completed in January 2025 with no dose-limiting toxicities observed up to 500 mg QD. Dose expansion initiated in April 2025 across two cohorts (320 mg and 500 mg QD), and in January 2026 an additional cohort was added to evaluate activity against BCR::ABL1 resistance mutations including T315I, M244V, and F359I/C/V. The FDA granted Orphan Drug Designation for TERN-701 in CML in March 2024. Clinical data reported to date indicate rates of major molecular response and deep molecular response by week 24, including in patients with high disease burden who had received multiple prior therapy lines, with low rates of severe adverse events and discontinuations. Specifically, Terns reported a 75% cumulative MMR rate by 24 weeks in 32 efficacy-evaluable patients. The strategic context The TERN-701 CML program joins a Merck hematology pipeline that already includes three Phase III candidates: bomedemstat (LSD1 inhibitor), nemtabrutinib (non-covalent BTK inhibitor), and zilovertamab vedotin (ROR1-targeting ADC), along with MK-1045 (CD19×CD3 T-cell engager) in Phase Ib/II. The Terns buyout extends a pattern of aggressive deal-making driven by the approaching Keytruda patent cliff (~2028). Merck’s recent transactions include the USD 9 billion purchase of influenza-focused Cidara Therapeutics, Inc. (Nasdaq: CDTX), the USD 10 billion purchase of Verona Pharma for a COPD therapy, and the USD 10.8 billion acquisition of immunology-focused Prometheus Biosciences. In the chronic myeloid leukemia treatment landscape, TERN-701 enters a competitive field. Novartis markets asciminib (Scemblix), the first approved allosteric BCR::ABL1 inhibitor, which received FDA approval in 2022 for Ph+ CML after two or more prior TKIs and gained a first-line CML indication based on the ASC4FIRST trial. Sun Pharma Advanced Research is developing denimsertib, another allosteric BCR::ABL1 inhibitor in clinical development. Earlier-generation ATP-competitive TKIs from Novartis (imatinib, nilotinib), Bristol Myers Squibb (dasatinib), and Pfizer (bosutinib) remain standards of care, though resistance mutations and tolerability limitations persist across these agents. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

AcquisitionOrphan DrugClinical ResultDrug ApprovalPhase 3

05 Feb 2026

·firstwordpharma.com

Eliquis price cut drives upbeat guidance for BMS

Bristol Myers Squibb on Thursday released its sales forecast for the current year, with the expected range of between $46 billion and $47.5 billion surpassing analyst expectations of $44.2 billion. The guidance, although representing a decline versus 2025, when revenue reached $48.2 billion, includes continued growth for Eliquis. Sales of the factor Xa inhibitor had been expected to significantly decline this year after BMS and partner Pfizer announced that they will start selling the drug directly to US patients at more than 40% off the current list price following discussions with the Trump administration. Eliquis is also one of the first 10 medicines subject to Medicare price negotiations in the US under the ⁠Inflation Reduction Act, which came into effect on January 1.However, BMS said that sales of Eliquis are predicted to increase between 10% and 15% this year. The company indicated that the product's lower price will help it avoid penalties imposed by the Medicare programme."The broader pricing dynamics starting this year for Eliquis really ‍was the impetus to re-evaluate our pricing strategy," said Chief Commercialisation Officer Adam Lenkowsky. He explained that the price reduction "eliminates the inflationary penalties…of statutory rebates that had been accumulating over many years for the brand and, taken together, the continued increase in Eliquis market share in the [US], coupled with these net pricing changes, they're going to enable Eliquis to be an important driver of growth this year."According to BMS, the outlook for 2026 includes a 12% to 16% revenue decline for its older portfolio of drugs — Abraxane, Revlimid and Sprycel, which are facing generic competition — partially offset by growth from newer products, as well as the uptick for Eliquis. Earnings per share for the current year are seen in the range of $6.05 to $6.35, versus predictions of $6.02 per share.'Data-rich' yearCEO Christopher Boerner called 2026 "data-rich" for the company, adding "our core business is strong and growing, and we have the potential to achieve industry-leading, sustainable growth into the 2030s and beyond."In the final quarter of 2025, sales of BMS's newer drugs rose 16% to $7.4 billion, driven by immuno-oncology products, Camzyos, Breyanzi and Reblozyl. Revenue from older drugs slipped 15% to $5.1 billion, as overall sales increased 1% to $12.5 billion, topping analyst estimates of $12.3 billion.Fourth-quarter sales of Reblozyl climbed 22% to $666 million, Breyanzi lifted 49% to $392 million and revenue from Camzyos surged 59% to $353 million. Meanwhile, the PD-L1 inhibitor Opdivo posted sales of $2.7 billion, up 9% year-on-year, and topping forecasts of $2.3 billion."We made significant progress in 2025, with real momentum in our growth portfolio," said Boerner. However, BMS's biggest seller continues to be one of its older drugs in Eliquis, with revenue in the three-month period growing 8% to $3.5 billion, boosted by higher demand. Net income in the fourth quarter was $1.1 billion, versus just $72 million in the same period of 2024. Meanwhile, net income for the full year was $7.1 billion, compared with a loss of $8.9 billion a year earlier.

Financial StatementBiosimilarAccelerated ApprovalDrug Approval

04 Feb 2026

·www.prnewswire.com

Lupin Launches Dasatinib Tablets in the United States

Feb. 2, 2026 -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the launch of Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, in the United States, following the approval for its Abbreviated New Drug Application (ANDA) from the U.S. FDA. The product was developed in partnership with Pharmascience Inc. Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg are bioequivalent to Sprycel® Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, of Bristol-Myers Squibb Company, and indicated for the treatment of: newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+CML with resistance or intolerance to prior therapy including imatinib adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy pediatric patients 1 year of age and older with Ph+ CML in chronic phase pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy Dasatinib Tablets (RLD Sprycel®) had an estimated annual sale of USD 930 million in the U.S. (IQVIA MAT Oct 2025). Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. Pharmascience Inc. is one of the largest pharmaceutical manufacturers in Canada, headquartered in Montreal. The company delivers high quality medicines to more than 50 countries worldwide. Pharmascience Inc.'s global presence and agile business development model support healthcare communities with dependable, Canadian-produced therapies designed to meet evolving patient needs. The content above comes from the network. if any infringement, please contact us to modify.

Drug Approval

100 Deals associated with Dasatinib

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D06414	Dasatinib	L01XE06	DB01254

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Aggressive-Phase Chronic Myelocytic Leukemia	European Union	Accord Healthcare SL	26 Jul 2024
Aggressive-Phase Chronic Myelocytic Leukemia	Iceland	Accord Healthcare SL	26 Jul 2024
Aggressive-Phase Chronic Myelocytic Leukemia	Liechtenstein	Accord Healthcare SL	26 Jul 2024
Aggressive-Phase Chronic Myelocytic Leukemia	Norway	Accord Healthcare SL	26 Jul 2024
Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase	European Union	Accord Healthcare SL	26 Jul 2024
Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase	Iceland	Accord Healthcare SL	26 Jul 2024
Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase	Liechtenstein	Accord Healthcare SL	26 Jul 2024
Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase	Norway	Accord Healthcare SL	26 Jul 2024
Philadelphia chromosome positive chronic myelogenous leukemia	European Union	Bristol-Myers Squibb Pharma EEIG	20 Nov 2006
Philadelphia chromosome positive chronic myelogenous leukemia	Iceland	Bristol-Myers Squibb Pharma EEIG	20 Nov 2006
Philadelphia chromosome positive chronic myelogenous leukemia	Liechtenstein	Bristol-Myers Squibb Pharma EEIG	20 Nov 2006
Philadelphia chromosome positive chronic myelogenous leukemia	Norway	Bristol-Myers Squibb Pharma EEIG	20 Nov 2006
Philadelphia positive acute lymphocytic leukaemia	European Union	Bristol-Myers Squibb Pharma EEIG	20 Nov 2006
Philadelphia positive acute lymphocytic leukaemia	Iceland	Bristol-Myers Squibb Pharma EEIG	20 Nov 2006
Philadelphia positive acute lymphocytic leukaemia	Liechtenstein	Bristol-Myers Squibb Pharma EEIG	20 Nov 2006
Philadelphia positive acute lymphocytic leukaemia	Norway	Bristol-Myers Squibb Pharma EEIG	20 Nov 2006
Acute Lymphoblastic Leukemia	United States	Bristol Myers Squibb Co.	28 Jun 2006
Blast Phase Chronic Granulocytic Leukemia	United States	Bristol Myers Squibb Co.	28 Jun 2006
Chronic phase chronic myeloid leukemia	United States	Bristol Myers Squibb Co.	28 Jun 2006

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Myelogenous Leukemia	NDA/BLA	United States	Xspray Pharma AB	18 Nov 2021
Castration-Resistant Prostatic Cancer	Phase 3	United States	Bristol Myers Squibb Co.	01 Oct 2008
Castration-Resistant Prostatic Cancer	Phase 3	Argentina	Bristol Myers Squibb Co.	01 Oct 2008
Castration-Resistant Prostatic Cancer	Phase 3	Australia	Bristol Myers Squibb Co.	01 Oct 2008
Castration-Resistant Prostatic Cancer	Phase 3	Brazil	Bristol Myers Squibb Co.	01 Oct 2008
Castration-Resistant Prostatic Cancer	Phase 3	Canada	Bristol Myers Squibb Co.	01 Oct 2008
Castration-Resistant Prostatic Cancer	Phase 3	Czechia	Bristol Myers Squibb Co.	01 Oct 2008
Castration-Resistant Prostatic Cancer	Phase 3	Finland	Bristol Myers Squibb Co.	01 Oct 2008
Castration-Resistant Prostatic Cancer	Phase 3	France	Bristol Myers Squibb Co.	01 Oct 2008
Castration-Resistant Prostatic Cancer	Phase 3	Germany	Bristol Myers Squibb Co.	01 Oct 2008

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00254423 (CTgov)	Phase 2	Chronic phase chronic myeloid leukemia \| Philadelphia chromosome positive chronic myelogenous leukemia	150	dasatinib	gywoiyuizw = whpouzukwp gmrnjnrnyl (cimpempwla, pudxdbptsl - gfnfcmaqhd) View more	-	15 Jan 2026
NCT03654768 (CTgov)	Phase 2	Chronic phase chronic myeloid leukemia	81	dasatinib+nilotinib+imatinib+bosutinib (Single Agent TKI)	ewkufozejv = bnrwmnwaiv ftphnaergn (aybgmxglfj, mltyhskuzt - xkflkulegb) View more	-	18 Dec 2025
				Ruxolitinib (TKI + Ruxolitinib)	ewkufozejv = vzshcfyaxy ftphnaergn (aybgmxglfj, yfozaxeujl - ukdqtazzzs) View more
NCT05042531 (ASH2025)	Phase 2	Acute Myeloid Leukemia Maintenance	30	Azacitidine	qlkzdukxhx(yclaohjezt) = vjncdbvbni rotlneczvb (seaekvaacz, 18.9 - 33.1) View more	Positive	06 Dec 2025
				Azacitidine + Dasatinib	nprgryewny(ujqmnfkbgg) = lxxdtthxeg gcuudtfhka (rfeogqakui ) View more
ASH2025	Not Applicable	Chronic phase chronic myeloid leukemia	58	Low-dose generic dasatinib (50 MG/Day)	mogmykehhm(eefbqdbake) = tovsbbhzxt mvbcaxhsmw (tnaxzwarqz ) View more	Positive	06 Dec 2025
				Generic imatinib (400 MG/Day)	mogmykehhm(eefbqdbake) = oxgzhcluov mvbcaxhsmw (tnaxzwarqz ) View more
ASH2025	Not Applicable	Philadelphia positive acute lymphocytic leukaemia	958	imatinib	ipdpzfzjji(mkrzvyughy) = fmlyvmxwuv kxjtlgcpcc (xlhwxpfhxx ) View more	Positive	06 Dec 2025
				dasatinib	ipdpzfzjji(mkrzvyughy) = zkyiwjhlbf kxjtlgcpcc (xlhwxpfhxx ) View more
SWOG 1318 (ASH2025)	Phase 2	Philadelphia positive acute lymphocytic leukaemia First line Philadelphia chromosome positive	24	Dasatinib, prednisone, and blinatumomab combination therapy	bmrxlsiswj(vckqwkuqoh) = tkskasinkh dzbmzytznd (znidtnquvi ) View more	Positive	06 Dec 2025
KISS (ASH2025)	Phase 2	Chronic phase chronic myeloid leukemia First line	96	Imatinib	eygaejfoix(mdgntdefzc) = pqtogthbwr qjaeronhlc (zwjyrlrnub, 73 - 94) View more	Positive	06 Dec 2025
ASH2025	Not Applicable	Chronic phase chronic myeloid leukemia	530	imatinib	twfwjjkvdx(qyctmldvsj) = tzoqknpdag qvffkvtngp (rkwvoklufx ) View more	Positive	06 Dec 2025
				nilotinib	twfwjjkvdx(qyctmldvsj) = gbfpuzwuiu qvffkvtngp (rkwvoklufx ) View more
ASH2025	Not Applicable	-	212	Intensive Chemotherapy (IC)	wpkypbjvrg(fhdhqljzbb) = waxclqdmke aawffyidwc (ighksmyevt ) View more	Positive	06 Dec 2025
				Intensive Chemotherapy + Tyrosine Kinase Inhibitor (IC + TKI)	wpkypbjvrg(fhdhqljzbb) = jdyoleemmq aawffyidwc (ighksmyevt ) View more
NCT00869401 (North Central Cancer Treatment Group N0877 (alliance), Pubmed \| Neuro Oncol)	Phase 2	Glioblastoma	204	Dasatinib with standard concurrent and adjuvant TMZ	zccjieidlw(cldtffgwtc) = hzsgptjsff tijeeycpvv (shkiymwmqw )	Negative	01 Oct 2025
				Placebo with standard concurrent and adjuvant TMZ	zccjieidlw(cldtffgwtc) = krtpgngcnz tijeeycpvv (shkiymwmqw )